RISPERIDEX 3 MG

国: イスラエル

言語: 英語

ソース: Ministry of Health

即購入

公開評価報告書 公開評価報告書 (PAR)
20-08-2020

有効成分:

RISPERIDONE

から入手可能:

DEXCEL PHARMA TECHNOLOGIES LTD

ATCコード:

N05AX08

医薬品形態:

TABLETS

構図:

RISPERIDONE 3 MG

投与経路:

PER OS

処方タイプ:

Required

製:

DEXCEL LTD, ISRAEL

治療群:

RISPERIDONE

治療領域:

RISPERIDONE

適応症:

Risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years.Risperidone is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

承認日:

2021-05-31

他の言語のドキュメント

情報リーフレット 情報リーフレット アラビア語 10-11-2020
情報リーフレット 情報リーフレット ヘブライ語 23-05-2019

この製品に関連するアラートを検索

ドキュメントの履歴を表示する